The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ravulizumab IV in pediatric participants to support the extrapolation of efficacy from the adult population.
Who is eligible:
Children and adolescents ages 2 to less than 18 years of age at the time of signing the informed consent with IgA Nephropathy or IgA Vasculitis Nephritis
